Clinical Trial Update: Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 12 weeks of sofosbuvir plus ribavirin in adults with chronic hepatitis C genotype 2 or 3 who are interferon intolerant or unwilling, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-02-17